Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.

Bibliographic Details
Main Author:	PLOS ONE Editors
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6459487?pdf=render

id	doaj-16e1f99abae049cbb3504bc33e2fa90b
record_format	Article
spelling	doaj-16e1f99abae049cbb3504bc33e2fa90b2020-11-25T02:29:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01144e021510910.1371/journal.pone.0215109Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.PLOS ONE Editorshttp://europepmc.org/articles/PMC6459487?pdf=render
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	PLOS ONE Editors
spellingShingle	PLOS ONE Editors Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors. PLoS ONE
author_facet	PLOS ONE Editors
author_sort	PLOS ONE Editors
title	Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
title_short	Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
title_full	Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
title_fullStr	Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
title_full_unstemmed	Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.
title_sort	expression of concern: antitumor activity of sorafenib in human cancer cell lines with acquired resistance to egfr and vegfr tyrosine kinase inhibitors.
publisher	Public Library of Science (PLoS)
series	PLoS ONE
issn	1932-6203
publishDate	2019-01-01
url	http://europepmc.org/articles/PMC6459487?pdf=render
work_keys_str_mv	AT plosoneeditors expressionofconcernantitumoractivityofsorafenibinhumancancercelllineswithacquiredresistancetoegfrandvegfrtyrosinekinaseinhibitors
_version_	1724833326959689728

Expression of Concern: Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors.

Similar Items